manilatimes1 小时
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following ...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive Phase 2 results for two novel monoclonal antibodies targeting distinct domains of Factor XI. REGN7508 (catalytic domain) is ...